Table 4

Summary of results for “investigators’ global assessment of response”a from a meta-analysis by Ashcroft, et al.

Number of included studiesRelative riskb (95% CI)
At 3 weeks
Pimecrolimus compared with vehicle52.72 (1.84 to 4.03)
Pimecrolimus compared with BMV 0.1%10.22 (0.09 to 0.54)
Tacrolimus 0.03% compared with vehicle12.13 (1.24 to 3.68)
Tacrolimus 0.1% compared with vehicle11.57 (0.88 to 2.81)
Tacrolimus 0.03% compared with tacrolimus 0.1%30.89 (0.67 to 1.19)
Tacrolimus 0.03% compared with HCA 1%22.56 (1.95 to 3.36)
Tacrolimus 0.1% compared with HCA 1%13.05 (2.12 to 4.40)
Tacrolimus 0.03% compared with HB 0.1%10.73 (0.58 to 0.93)
Tacrolimus 0.1% compared with HB 0.1%10.95 (0.78 to 1.17)
At 6 weeks
Pimecrolimus compared with vehicle32.03 (1.50 to 2.74)
Pimecrolimus compared with tacrolimus 0.03%10.71 (0.45 to 1.12)
At 12 weeks
Tacrolimus 0.03% compared with vehicle34.50 (2.91 to 6.96)
Tacrolimus 0.1% compared with vehicle35.62 (3.67 to 8.61)
Tacrolimus 0.03% compared with tacrolimus 0.1%30.80 (0.65 to 0.99)
Tacrolimus 0.1% compared with HB 0.1%+HCA 1%11.67 (1.41 to 1.98)

a For pimecrolimus trials, “investigators’ global assessment of response” was determined by using IGA score ≤ 1 (clear or almost clear resolution of disease); for tacrolimus trials, “investigators’ global assessment of response” was determined as >90% improvement from baseline.

b Referred to as “rate ratio” in the publication.

Abbreviations: BMV, betamethasone valerate; HB, hydrocortisone butyrate; HCA, hydrocortisone acetate.

From: Results

Cover of Drug Class Review: Topical Calcineurin Inhibitors
Drug Class Review: Topical Calcineurin Inhibitors: Final Report [Internet].
Lee NJ, McDonagh M, Chan B, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.